Skip to content

Guide

How GLP-1 Medication Works

How does GLP-1 medication work for weight loss?

GLP-1 medications work by mimicking a hormone the gut releases after eating. They slow the rate at which the stomach empties and act on appetite centres in the brain, so hunger falls and fullness lasts longer after a meal. The result is that people eat less without the constant effort that usually makes calorie restriction fail. They do not burn fat directly, the weight change comes from reduced intake.

What is GLP-1?

Glucagon-like peptide-1, or GLP-1, is a hormone released by cells in the small intestine when food arrives. It is an incretin, a signal from the gut to the rest of the body that eating has happened and the system should respond accordingly.

Naturally released GLP-1 breaks down within minutes. The medicines in this class are engineered to resist that breakdown, which is why a single injection can act across a whole week rather than a few minutes.

This distinction matters when people ask whether these medicines are "natural". The hormone is; the duration is not. The therapeutic effect comes precisely from sustaining a signal the body normally produces only in short bursts.

Three effects that combine

The appetite change people describe is not one mechanism but several acting together, which is why the experience differs from a stimulant appetite suppressant.

Delayed gastric emptying
Food remains in the stomach longer, so physical fullness persists for hours rather than minutes after a meal.
Central appetite regulation
Receptors in the hypothalamus and brainstem respond, reducing hunger signals and the intrusive food-related thoughts many people describe as "food noise".
Glucose-dependent insulin release
Insulin release is stimulated only when blood glucose is raised, which is why these medicines carry a low risk of hypoglycaemia when used alone.

Why some treatments act on two receptors

Tirzepatide, the active ingredient in Mounjaro, acts on a second incretin receptor as well: glucose-dependent insulinotropic polypeptide, or GIP. Semaglutide, in Wegovy, acts on GLP-1 alone.

The clinical significance of adding GIP was an open question until the treatments were compared directly. In the SURMOUNT-5 trial, published in the New England Journal of Medicine, tirzepatide produced a 20.2% mean weight reduction against 13.7% for semaglutide across 72 weeks.

That does not make one treatment correct for everyone. Tolerability, other medical conditions, existing medicines and individual response all bear on which is appropriate, and that judgement belongs to a prescriber.

What the mechanism means in practice

Because the effect works through appetite rather than metabolism, the medicine creates an opportunity rather than a result. Eating less becomes achievable; what is eaten still determines the outcome.

This explains two things people find surprising. First, protein and resistance exercise matter more on treatment than off it, because weight lost without them includes more muscle. Second, appetite generally returns when treatment stops, which is why a maintenance plan is part of the clinical picture rather than an afterthought.

It also explains the most common side effects. Slowing the stomach is the mechanism, so nausea, fullness and altered bowel habit are the mechanism showing itself, most noticeably in the days after a dose increase.

GLP-1 in tablet or liquid form: what is authorised and what is not

This is one of the most searched questions about these medicines, and until 2026 the answer was short: for weight management, every authorised treatment was an injection. That is no longer true, and the change matters more than most news in this field.

Two tablets are now licensed for weight management. They are not variations on each other — they are different molecules with different rules, and the rules are the part that decides whether a tablet works for a given person.

Wegovy tablets (oral semaglutide), once daily
The same active ingredient as the Wegovy injection, in a tablet. Started at 1.5 mg and escalated through 4 mg and 9 mg to a 25 mg maintenance dose, with at least a month at each step. It must be swallowed on an empty stomach after at least 8 hours without food, with no more than half a glass of water — up to 120 ml — and nothing may be eaten, drunk or taken by mouth for at least 30 minutes afterwards. Eating sooner reduces how much is absorbed. One tablet a day, never two to make a larger dose.
Foundayo (orforglipron), once daily
A small molecule rather than a peptide, which is why it has none of those conditions: any time of day, with or without food, no limit on water. Started at 0.8 mg and escalated to as much as 17.2 mg, at least 30 days at each step. Licensed in the UK on 10 August 2026 for weight management and, separately, for type 2 diabetes.
Rybelsus (oral semaglutide), once daily — for diabetes
The tablet that existed before either of the above, centrally authorised across the EU since 3 April 2020 at lower doses. Its indication is type 2 diabetes, not weight management. It shares the fasting and 30-minute rules, and it is a separate product from Wegovy tablets rather than another name for them.

Liquid GLP-1, drops and patches: why none of them is the medicine

Searches for liquid GLP-1 — how often to take it, what time of day, whether it works on an empty stomach — are among the most common in this category, and they deserve a direct answer rather than a warning.

There is no licensed liquid GLP-1 for weight management anywhere. Every authorised GLP-1 receptor agonist is either an injection or one of the tablets above. So the capsules, drops, patches, gummies and "liquid GLP-1" sold online and from shop shelves are not low-strength versions of the medicine; they are a different kind of product altogether. They contain no GLP-1 receptor agonist, and they have been through no process in which either effectiveness or safety was assessed.

Which means the timing questions have no answer, and that absence is the useful finding. There is no correct dose, no best time of day and no fasting rule for a product with no active ingredient and no authorised dosing instructions, and a label that supplies one has invented it. If you are looking for how to take oral GLP-1 properly, the instructions above are the real ones, and they belong to medicines a prescriber has to write for you.

The reliable test takes a moment: a GLP-1 receptor agonist is prescription-only in every market this site serves. Anything that can be added to a basket without an assessment is, by that fact alone, not one.

Common questions

Should GLP-1 tablets be taken on an empty stomach?

It depends which tablet. Semaglutide tablets — Wegovy tablets for weight management, Rybelsus for type 2 diabetes — must be taken fasting, after at least 8 hours without food, with no more than 120 ml of water, and nothing eaten, drunk or taken by mouth for at least 30 minutes afterwards; eating sooner substantially reduces how much is absorbed. Foundayo (orforglipron) has no such requirement and is taken at any time of day, with or without food.

Is there a GLP-1 in tablet form?

Yes, and since 2026 there is one licensed for weight management rather than only for diabetes. Wegovy tablets (oral semaglutide, up to 25 mg daily) and Foundayo (orforglipron, up to 17.2 mg daily) are both licensed for weight management; Rybelsus is oral semaglutide at lower doses for type 2 diabetes. All three are prescription-only. The capsules, drops and patches sold as “GLP-1” are none of them and contain no GLP-1 receptor agonist.

How often do you take oral GLP-1?

Once a day, for every licensed oral GLP-1 — Wegovy tablets, Foundayo and Rybelsus alike — as against once a week for most of the injections. One tablet per day is the whole dose; taking two to reach a higher dose is specifically warned against in the licences, because it does not work that way and increases side effects. There is no licensed liquid or drop form, so no dosing schedule exists for one.

What is the best time of day to take oral GLP-1?

For semaglutide tablets, first thing, because the 8-hour fast before and the 30-minute wait afterwards are easiest to fit around sleep — and because taking it later means a second fast in the same day. For Foundayo there is no best time; the licence sets none, so the best time is whichever one you will remember. Consistency matters more than the hour in both cases.

Does liquid GLP-1 work?

There is no licensed liquid GLP-1 for weight management, so the question has no product behind it. The liquids and drops sold under that name contain no GLP-1 receptor agonist and have been assessed for neither effectiveness nor safety. The licensed oral options are tablets, and both are prescription-only.

Do GLP-1 medications burn fat?

No. GLP-1 medications do not burn fat or raise metabolic rate directly. They reduce appetite and slow gastric emptying, which lowers how much a person eats. The weight change follows from that reduced intake, which is why dietary and activity changes remain necessary.

What is "food noise" and why does it stop?

Food noise describes intrusive, recurring thoughts about eating. GLP-1 receptors in the brain are involved in appetite and reward signalling, and activating them reduces those signals. Many people report this as the most noticeable change, often before any weight change is measurable.

Why does nausea happen after a dose increase?

Nausea is the medicine's primary mechanism becoming noticeable. Delayed gastric emptying is how these treatments work, and each dose increase intensifies that effect before the body adapts. This is why doses are raised gradually, with at least four weeks between increases.

Is GLP-1 medication a lifelong treatment?

Not necessarily, but appetite typically returns to its previous level once treatment stops, and weight regain is common without a structured maintenance plan. Duration is a clinical decision made with your prescriber, based on your response, tolerability and wider health.

Sources

Medical review

Rachael Frances Allison

Pharmacist Independent Prescriber

Last updated